Business
Unseen Capital funds entrepreneurs of early-stage healthcare companies focused on addressing the needs of underserved communities.
The company will use the funds to expand its workforce, including its sales team, in order to broaden its biopharma partnerships.
The funding comes a year after the company announced an expanded relationship with OpenAI to develop a chatbot for healthcare providers built on GPT-4.
It has also received Australia's regulatory approval for its AI solution.
The company will use the investment to expand its reach across the U.S. and develop new technologies.
The acquisition allows Uwill to provide access to mental health support to more than three million students at 400 colleges worldwide.
Also, New Zealand's The Doctors has cautioned the public about a mobile app posing as its official app.
The company's first two partners to leverage OMNY's dataset are life sciences company ArisGlobal and clinical trial design company QuantHealth.
The company will use the funds to scale its growth within healthcare systems and expand its AI innovation.
Rad AI's genAI tools will be offered through Bayer's vendor-neutral Calantic Digital Solution marketplace, which provides AI-enabled clinical and operational applications.